B
BioTheranostics
Biotech & Life Sciences · San Diego, United States · Founded 1996
Extensive research generates high-complexity molecular tools that help physicians execute more informed treatment decisions MoreLess
Biotheranostics, headquartered in San Diego, CA, specializes in genomic testing for oncology, focusing on breast and metastatic cancers. The company offers proprietary genomic assays, such as the Breast Cancer Index, which is the only test recognized by both the ASCO and NCCN Clinical Practice Guidelines. These tests help predict the benefit of extended endocrine therapy in hormone receptor-positive, early-stage breast cancer, and identify tumor types and subtypes in metastatic cancer patients with unclear diagnoses. Acquired by Hologic in February 2021, Biotheranostics continues to support personalized disease management in oncology. The company primarily serves oncologists and healthcare providers, operating within the precision medicine market. Biotheranostics generates revenue through the sale of its genomic tests, which are used to guide treatment decisions and improve patient outcomes.
Keywords: genomic testing, oncology, breast cancer, metastatic cancer, personalized medicine, hormone receptor-positive, endocrine therapy, tumor identification, precision medicine, healthcare providers.
Company overview
BioTheranostics company information
The essential company record, classifications and operating signals in one place.
- Status
- Acquired
- Founded
- 1996
- Headquarters
- San Diego, United States
- Employees
- 97
- Open positions
- None listed
- Dealroom signal
- 32.3
Valuation & funding
BioTheranostics funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITION✓Exit | Feb 2021 | $230M | $230M | Hologic | ↗ |
| GROWTH EQUITY VC✓Equity / VC | Jan 2016 | $32M | — | Evidity Health Capital · MVM Life Science Partners · HealthQuest Capital | — |
| ACQUISITION✓Exit | Sep 2008 | $60M | $60M | BioMérieux | ↗ |
| SERIES A✓Equity / VC | Jan 2008 | $8M | $32M | Undisclosed | — |
Financials
Revenue and workforce over time
Available revenue and workforce history. Fields without reported data are omitted.
| Year | Revenue | Growth | Employees |
|---|---|---|---|
| 2026 | $33M | 0% | 96 |
| 2025 | $33M | 0% | 116 |
| 2024 | $33M | 0% | 116 |
| 2023 | $33M | 0% | 116 |
| 2022 | $33M | 0% | 116 |
| 2021 | $33M | 0% | 122 |
| 2020 | $33M | — | 120 |
Growth signals
BioTheranostics website traffic
Latest recorded traffic for BioTheranostics is 240 monthly website visits, down 36.8% over the last three months. BioTheranostics's team declined 16.4% over the past year.
Comparisons
BioTheranostics compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Talent graph
BioTheranostics's talent
Source: Dealroom Talent Intelligence.
Investors
5 investors on BioTheranostics's cap table
Sourced from Dealroom's funding and investor records.
Global footprint
Where BioTheranostics has talent and traffic
team presence
In the news
Latest news about BioTheranostics
Recent press, funding announcements, and product moves mentioning BioTheranostics — open to read from the original sources.
Market sentiment
What the market is saying about BioTheranostics
An AI-synthesized read of the highest-engagement posts about BioTheranostics on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See BioTheranostics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.